KYMR241115C50000
- 3.30
- +0.55+20.00%
Kymera Therapeutics Newsroom
Earnings Preview: KYMR to Report Financial Results Pre-market on October 31
Leerink Partners Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Kymera Therapeutics' Application for KT-621 Gets FDA Clearance
Express News | Kymera Therapeutics Inc - to Start Phase 1 Trial for KT-621 in October 2024
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
The Analyst Landscape: 7 Takes On Kymera Therapeutics
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Kymera Therapeutics Price Target Raised to $56 From $52 at Oppenheimer
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $60
Kymera Therapeutics Says Its Potential IND KT-621 Reduced Inflammation in Preclinical Models
Express News | Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Leerink Partners Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $60
Express News | Kymera Therapeutics Inc : Leerink Partners Assumes Coverage With Outperform Rating; Target Price $60